Skip to main
MGTX
MGTX logo

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings PLC is poised for a positive trajectory with an extended financial runway projected through 2027, following the anticipated closing of the Hologen deal. The company's focus on providing one-time functional cures in ophthalmology has shown promising outcomes, as evidenced by the improvement in binocular visual acuity across all patients in recent trials and significant benefits in patient-reported outcomes. Furthermore, the planned Biologics License Application (BLA) filing in 2026, combined with the promising Phase II trial results and RMAT designation, underscores the potential for significant advancements in gene therapy for various disorders.

Bears say

The fundamental reasons for the negative outlook on MeiraGTx Holdings PLC's stock can be attributed to significant uncertainties surrounding regulatory approvals for its gene therapy products, which could lead to downward revisions in risk-adjusted projections and financial estimates. Additionally, the company's recent net loss of $148 million, equating to an earnings per share (EPS) of ($2.12), exceeded earlier estimates, indicating financial strain. Finally, the potential for manufacturing challenges and a pricing structure that may not align with established norms in the therapeutic market further compounds the risks associated with the company's current and future financial performance.

MGTX has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Buy based on their latest research and market trends.

According to 6 analysts, MGTX has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.